<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560414</url>
  </required_header>
  <id_info>
    <org_study_id>2017L09</org_study_id>
    <nct_id>NCT03560414</nct_id>
  </id_info>
  <brief_title>The Plasma Diafiltration Therapy of Hepatic Failure</brief_title>
  <official_title>Study of High - Flux Plasma Diafiltration Based on Plasma - Saved Mode in the Treatment of Patients With Hepatic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there is no comparative study between the simple plasma exchange and plasma
      diafiltration (PDF), and no further exploration of optimal plasma dose in PDF treatment.
      Therefore, this prospective randomized cohort study aims to compare the safety and
      effectiveness of the tree groups（simple plasma exchange group, conventional PDF treatment
      group, less plasma PDF treatment group）by collecting SOFA score, 3-month survival rate, MELD
      score, and the times of artificial liver treatment , blood cell variables, cytokines(e.g.
      TNFα ), pre- and post-treatment plasma ammonia levels. Thus, it is to provide a safer and
      more effective artificial liver treatment with less plasma dose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Model for end-stage liver disease （MELD score）</measure>
    <time_frame>month 3</time_frame>
    <description>MRLD=R=3.8ln[TBIL(mg/dl)]+11.2ln(INR)+9.6ln [Cr(mg/dl)]+6.4(etiology：Bile or alcoholic 0，others 1)。</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokine</measure>
    <time_frame>Month 3</time_frame>
    <description>The concentration of cytokines（TNF-α、IL-６、IL-８、IL-10）will be tested</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood platelet count</measure>
    <time_frame>Month 3</time_frame>
    <description>To observe the changes in platelet count before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of artificial liver treatment</measure>
    <time_frame>Month3</time_frame>
    <description>Count the number of artificial liver treatments during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the concentration of plasma ammonia</measure>
    <time_frame>Month 3</time_frame>
    <description>To observe the changes of plasma ammonia before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sequential organ failure assessment score（SOFA score）</measure>
    <time_frame>Month 3</time_frame>
    <description>PaO₂（0：&gt;53.33，1：39-53.33，2：26.66-40，3：13.33-26.67，4：≤13.33）；Platelet count（10/L）（0：&gt;150，1：101-150，2：51-100，3：21-50，4：&lt;21）；Respiratory support（3：NO，4：yes）；TBIL（0：&lt;20，1：20-32，2：33-101，3：102-204，4：&gt;204）；Glasgow Coma Scale（0：15，1：13～14，2：10～12，3：6～9，4：&lt;6）；Cr(umol/L)（0：&lt;110，1：110-170，2：171-299，3：300-440，4：&gt;440）；Level of hypotension (vasopressor status for ≥1 hr)（0：No hypotension；1：MAP &lt;70，2：On vasopressors, dopamine &lt;5 µg/kg/min OR dobutamine (any dose)，3：Dopamine &gt;5 µg/kg/min OR Epi/Norepi &lt;0.1µg/kg/min；4：Dopamine &gt;15 µg/kg/min OR Epi/Norepi &gt;0.1 µg/kg/min）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>Month 3</time_frame>
    <description>To count the survival rate after the treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatic Failure</condition>
  <condition>Plasma Exchange</condition>
  <arm_group>
    <arm_group_label>simple plasma exchange group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional PDF treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>less plasma PDF treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>simple plasma exchange</intervention_name>
    <description>simple plasma exchange treatment</description>
    <arm_group_label>simple plasma exchange group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional PDF treatment group</intervention_name>
    <description>conventional PDF treatment group</description>
    <arm_group_label>conventional PDF treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>less plasma PDF treatment group</intervention_name>
    <description>less plasma Plasma diafiltration treatment</description>
    <arm_group_label>less plasma PDF treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatic failure on Medium period

          -  Model for End-Stage Liver Disease (MELD) &lt;30 and &gt;20

          -  age &gt; 18 years and &lt;70years

          -  Written informed consent

        Exclusion Criteria:

          -  Active bleeding or disseminated intravascular coagulation

          -  allergic to blood products or drugs such as plasma, heparin and protamine

          -  hemodynamic instability

          -  cardiovascular and cerebrovascular accidental infarction instability Period

          -  extravascular hemolysis

          -  severe sepsis

          -  Tumor on ultrasonography, CT or MRI examination

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zhiyu zeng</last_name>
    <phone>008615880447131</phone>
    <email>498289727@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuzhou General Hospital, Xiamen Univ</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fuzhou General Hospital</investigator_affiliation>
    <investigator_full_name>Dongliang Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

